Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1892-1900

  Dong, Maoqing ^a   Hadac, Elizabeth M ^a   Pinon, Delia I ^a   Miller, Laurence J ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CYANOGEN BROMIDE; PHENYLALANINE; TRYPTOPHAN; PEPTIDE FRAGMENT; TETRAGASTRIN;

AFFINITY LABELING; AGONIST; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; COVALENT BOND; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; RADIOCHEMISTRY; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CHO CELL; DOSE RESPONSE; GENETICS; HAMSTER; METABOLISM; MOLECULAR GENETICS; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RECEPTOR, CHOLECYSTOKININ A; TETRAGASTRIN;

EID: 21744435941     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.012179     Document Type: Article

References (33)

1. Arlander SJ, Dong M, Ding XQ, Pinon DI, and Miller LJ (2004) Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist and antagonist. Mol Pharmacol 66:545-552.
2. Bodanszky M, Natarajan S, Hahne W, and Gardner JD (1977) Cholecystokinin (pancreozymin). 3. Synthesis and properties of an analogue of the C-terminal heptapeptide with serine sulfate replacing tyrosine sulfate. J Med Chem 20:1047-1050.
3. Bodanszky M, Tolle JC, Gardner JD, Walker MD, and Mutt V (1980) Cholecystokinin (pancreozymin). Synthesis and properties of the N alpha-acetyl-derivative of cholecystokinin 27-33. Int J Pept Protein Res 16:402-411.
4. Dawson ES, Henne RM, Miller LJ, and Lybrand TP (2002) Moleular models for cholecystokinin-A receptor. Pharmacol Toxicol 91:290-296.
5. Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, and Miller LJ (2001) Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe. J Biol Chem 276:4236-4244.
6. Ding XQ, Pinon DI, Furse KE, Lybrand TP, and Miller LJ (2002) Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol 61:1041-1052.
7. Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, and Miller LJ (1999) Structurally related peptide agonist, partial agonist and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis. J Biol Chem 274:4778-4785.
8. Dong M, Li Z, Pinon DI, Lybrand TP, and Miller LJ (2004) Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem 279:2894-2903.
9. Dong M, Liu G, Pinon, PI, and Miller LJ (2005) Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry, in press.
10. Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, et al. (2002) The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process. J Biol Chem 277:7546-7555.
11. Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, et al. (1999) Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin. Protein Sci 8:2347-2354.
12. Gouldson P, Legoux P, Carillon C, Dumont X, Le Fur G, Ferrara P, and Shire D (2000) Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S. Eur J Pharmacol 389:115-124.
13. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
14. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, and Miller LJ (1996) Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas 13:130-139.
15. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, and Miller LJ (1999) A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem 42:2105-2111.
16. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, and Miller LJ (1998) Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem 273:12988-12993.
17. Harikumar KG and Miller LJ (2002) Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor. Pharmacol Toxicol 91:286-289.
18. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, and Miller LJ (1997) Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 272:24393-243401.
19. Kennedy K, Escrieut C, Dufresne M, Clerc P, Vaysse N, and Fourmy D (1995) Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biophys Res Commun 213:845-852.
20. Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Frehel D, Gully D, Vaysse N, and Fourmy D (1997) Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem 272:2920-2926.
21. Klueppelberg UG, Gaisano HY, Powers SP, and Miller LJ (1989) Use of a nitrotryptophan-containing peptide for photoaffinity labeling the pancreatic cholecystokinin receptor. Biochemistry 28:3463-3468.
22. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
23. Miller LJ and Lybrand TP (2002) Molecular basis of agonist binding to the type A cholecystokinin receptor. Pharmacol Toxicol 91:282-285.
24. 125I-desaminotyrosyl-)CCK-8 and its interactions with pancreatic acini. J Biol Chem 256:12417-12423.
25. Munson PJ and Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
26. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, and Roques BP (1999) International Union of Pharmacology. XXI. Structure, distribution and functions of cholecystokinin receptors. Pharmacol Rev 51:745-781.
27. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
28. Pearson RK, Miller LJ, Hadac EM, and Powers SP (1987) Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J Biol Chem 262:13850-13856.
29. Powers SP, Pinon DI, and Miller LJ (1988) Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. Int J Pept Protein Res 31:429-434.
30. Rolland M, Rodriguez M, Lignon MF, Galas MC, Laur J, Aumelas A, and Martinez J (1991) Synthesis and biological activity of 2-phenylethyl ester analogues of C-terminal heptapeptide of cholecystokinin modified in Trp 30 region. Int J Pept Protein Res 38:181-192.
31. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5:434-444.
32. Silvente-Poirot S, Escrieut C, and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54:364-371.
33. Strader CD, Fong TM, Tota MR, Underwood D, and Dixon RA (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63:101-132.